RELPAX (eletriptan hydrobromide) by Viatris is 5-ht 1b , 5-ht 1d and 5-ht 1f receptors, has modest affinity for 5-ht 1a , 5-ht 1e , 5-ht 2b and 5-ht 7 receptors. Approved for cluster headache (), migraine, any subsequent attacks. First approved in 2002.
Drug data last refreshed 16h ago · AI intelligence enriched 1mo ago
RELPAX (eletriptan hydrobromide) is an oral triptan approved in 2002 for acute treatment of migraine and cluster headaches. It works by selectively binding to 5-HT 1B/1D serotonin receptors on intracranial blood vessels and trigeminal sensory nerves, causing cranial vasoconstriction and inhibiting pro-inflammatory neuropeptide release.
Product is in late-stage lifecycle with modest commercial footprint (~$3M spend, 2.4K claims in 2023), signaling smaller specialist teams focused on retention rather than growth initiatives.
5-HT 1B , 5-HT 1D and 5-HT 1F receptors, has modest affinity for 5-HT 1A , 5-HT 1E , 5-HT 2B and 5-HT 7 receptors. Migraines are likely due to local cranial vasodilatation and/or to the release of sensory neuropeptides (vasoactive intestinal peptide, substance P and calcitonin gene-related peptide)…
Worked on RELPAX at Viatris? Share your interview experience or compensation data (+7 days Pro)
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.
TREXIMA and RELPAX Gastric Scintigraphy Inside and Outside a Migraine
Upgrade to Pro to access Medicare Part D spending data and other premium pharma intelligence.
Upgrade to Pro — $25/moWorking on RELPAX offers limited but stable career opportunities primarily in quality, analytics, and technical operations as the product transitions toward generic maturity. Roles are focused on manufacturing efficiency, regulatory maintenance, and technical compliance rather than commercial expansion or innovation.
2 open roles linked to this drug